Most of the human genome — 98 percent — is made up of DNA but doesn’t actually encode genes, the recipes cells use to build proteins. The vast majority of genetic mutations associated with cancer occur in these non-coding regions of the genome, yet it’s unclear how they might influence tumor development or growth. Now researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified nearly 200 mutations in non-coding DNA that play a functional role in cancer. Each of the mutations could represent a new target in the search for cancer drugs.
The study is published April 2 in
UC San Diego School of Medicine found nearly 200 mutations in non-coding DNA that play a functional role in cancer — about 199 more than were known before. Photo courtesy of Pixabay
“Most cancer-related mutations occur in regions of the genome outside of genes, but there are so incredibly many of them that it’s hard to know which are actually relevant and which are merely noise,” said senior author Trey Ideker, PhD, professor at UC San Diego School of Medicine and Moores Cancer Center. “Here for the first time we found about 200 mutations in non-coding DNA that are functional in cancer — and that’s about 199 more than we knew before.”
When doctors and scientists refer to “cancer genes,” they’re usually talking about the several hundred known genes that, when mutated, clearly help drive tumor formation and growth. When mutations occur within genes, they can shut down production of the protein that the gene encodes, or cause a malfunctioning version to be produced. For some of these cancer-related gene mutations, there are therapies that specifically target the mutation to inhibit tumor growth, an effort known as personalized or precision medicine.
Ideker and team wondered about all of the other, non-coding mutations in cancer. Almost no patient with cancer gets the same mutations. So what are all these mutations doing? Are they just noise? Or are they functional? And how do they differ between patients?
Researchers had previously tried looking for an answer in The Cancer Genome Atlas (TCGA), the National Institutes of Health’s database of genomic information from more than 15,000 human tumors representing many cancer types. But they found only one non-coding mutation that seemed to play a role in cancer (it’s called TERT).
According to Ideker, those previous attempts just couldn’t match up non-coding mutations to cancer cell behaviors. His team also relied on TCGA data, comparing the tumor samples of 930 cancer patients to normal tissue samples from the same patients, but this time the researchers added an extra step.
“The secret sauce was to look for changes in gene expression,” said Ideker, who is also founder of the UC San Diego Center for Computational Biology and Bioinformatics and co-director of the Cancer Cell Map Initiative.
After finding nearly 200 non-coding mutations that alter gene expression, the team tested three of them in the laboratory. They replicated the non-coding mutation in cells and observed the resulting changes in gene expression.
“One example that stood out was a non-coding mutation affecting a gene called DAAM1,” said first author Wei Zhang, PhD, a postdoctoral researcher in Ideker’s lab. “DAAM1 activation makes tumor cells more aggressive, and better able to invade surrounding tissues.”
Next, the researchers will try to combine these non-coding mutations with coding mutations and determine if there are subtypes — certain types of breast cancer that have a common pattern of both coding and non-coding mutations, for example. Their goal is to find actions for this information, such as whether or not a patient has a particular mutation pattern that can provide diagnostic or prognostic clues, or inform a particular approach to therapy.
Additional study co-authors include: Ana Bojorquez-Gomez, Daniel Ortiz Velez, Guorong Xu, Kyle S. Sanchez, John Paul Shen, Kevin Chen, Katherine Licon, Katrina M. Olson, Michael Ku Yu, Justin K. Huang, Hannah Carter, Emma K. Farley, Stephanie I. Fraley, Jason F. Kreisberg, UC San Diego; Collin Melton, and Michael Snyder, Sanford University.
This research was funded, in part, by the National Institutes of Health (U24CA184427, U54CA209891, P50GM085764, P41GM103504, R01GM070743, DP5OD017937), UC San Diego Altman Clinical and Translational Research Institute (UL1TR001442), Burroughs Wellcome Fund (Career Award 1012027), and the National Science Foundation (Career Award 1651855).
Disclosure: Trey Ideker is co-founder of Data4Cure, Inc. and has an equity interest in the company. Ideker also has an equity interest in Ideaya BioSciences, Inc. The terms of this arrangement have been reviewed and approved by UC San Diego, in accordance with its conflict of interest policies.